The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk for stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA).
❓ Unknown
FDA approves first factor XIa inhibitor for secondary stroke prevention
Just now
November 18, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
The FDA approved Sunharbo (asundexian), a new factor XIa inhibitor medication for stroke prevention in adults with recent mild-to-moderate ischemic strokes or high-risk TIAs. This is a pharmaceutical advancement by U.S. regulatory authorities with no direct connection to Iran.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
Just now •
Airstrikes on Kuwait and Bahrain Coincide with US Attack on Qeshm Island
2 min ago •
Iran's Internet Future on Optical Fibers
4 min ago •